A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Trial Profile

A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bexarotene; Methotrexate
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides
  • Focus Registrational; Therapeutic Use
  • Acronyms ALCANZA
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 10 Aug 2018 This trial has been completed in Belgium (end date 2018-07-06).
    • 09 May 2018 This trial has been completed in Spain.
    • 19 Feb 2018 Planned End Date changed from 1 Jul 2018 to 31 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top